WASHINGTON (Reuters) - U.S. health experts on Monday will weigh what could become the first nonprescription weight-loss drug approved for use in the United States, where nearly two-thirds of the population is overweight and obesity rates continue to rise.
The drug, GlaxoSmithKline's low-dose version of Xenical, will come before a U.S. Food and Drug Administration advisory panel for discussion about whether to allow over-the-counter sales.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!